Stelo Launch And Dispelling GLP-1s: Dexcom’s Sayer Speaks

Dexcom’s CEO, Kevin Sayer, ahead of this year’s Advanced Technologies & Treatments for Diabetes conference, shared an update on the company’s recent news, future strategy and where he feels the market is headed.  

• Source: Shutterstock

On 5 March, Dexcom announced the US Food and Drug Administration had granted clearance to its Stelo blood glucose monitor, the first of its kind that will be sold over the counter. 

Now, American type II diabetes patients who are not on insulin therapy will be able to easily access top-spec CGM...

More from Leadership

More from In Vivo

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By 

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.